We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GTM:NASDAQZoomInfo Technologies Inc. Analysis

Data as of 2026-06-20 - not real-time

$2.81

Latest Price

8/10Risk

Risk Level: High

Executive Summary

ZoomInfo Technologies (GTM) is trading at $2.81, far below its DCF‑derived fair value of $12.18, implying an upside of roughly 84% and a valuation grade of undervalued. The stock sits well under its 20‑day SMA (3.09), 50‑day SMA (4.60) and 200‑day SMA (7.97), while the RSI of 32 signals oversold conditions and the MACD histogram is positive, indicating a tentative bullish signal amidst a broader bearish trend. However, the company’s recent guidance cut triggered a federal securities law probe, raising regulatory risk and adding to the bearish sentiment reflected in decreasing volume and a 30‑day volatility of 133%. Financially, GTM boasts a low PE of 7.0 versus an industry average of 38.1, strong gross margins (86.7%), but modest revenue growth (1.5%) and a high debt‑to‑equity ratio (>100%).
The technical picture is mixed: price is below key moving averages and the beta of 1.55 suggests heightened market sensitivity, yet the DCF model and low price‑to‑book (0.56) point to significant upside if the regulatory cloud clears. Short‑term pressure from the investigation and guidance downgrade supports a defensive stance, while the launch of GTM.AI and integration with major AI platforms provide a potential catalyst for medium‑ to long‑term recovery. Investors should weigh the immediate downside risk against the substantial intrinsic value and growth prospects embedded in the AI data moat.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Guidance cut and ensuing securities law investigation
  • Price below all major moving averages and bearish technical trend
  • High volatility and beta indicating market sensitivity

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Substantial undervaluation relative to DCF fair value
  • Launch of GTM.AI and partnerships with AI platforms
  • Persisting regulatory uncertainty limiting upside

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong gross margins and low price‑to‑book offering a margin of safety
  • Potential to capture AI‑driven demand for verified B2B data
  • Resolution of regulatory issues could unlock the 84% upside potential

Key Metrics & Analysis

Financial Health

Revenue Growth1.50%
Profit Margin10.10%
P/E Ratio7.0
ROE8.12%
ROA2.72%
Debt/Equity106.56
P/B Ratio0.6
Op. Cash Flow$460.9M
Free Cash Flow$354.8M
Industry P/E38.1

Technical Analysis

TrendBearish
RSI31.9
Support$2.59
Resistance$3.88
MA 20$3.09
MA 50$4.60
MA 200$7.97
MACDBullish
VolumeDecreasing
Fear & Greed Index91.46

Valuation

Fair Value$12.18
Target Price$5.17
Upside/Downside83.87%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.55
Volatility132.58%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.